Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
Published Online: 2014-10-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Isamu Okamoto•Kazuhiko Nakagawa•Koichi Goto•Kosei Tajima•Makoto Maemondo•Makoto Nishio•Masahiro Fukuoka•Noboru Yamamoto•Nobuyuki Yamamoto•Ryosuke Harada•Seisuke Nagase•Shinji Atagi•Takashi Seto•Takeharu Yamanaka•Terufumi Kato•Toyoaki Hida•Yukio Hosomi
